Wang D.,Beifang Hospital of Shenyang |
Guo X.-Z.,Beifang Hospital of Shenyang |
Li H.-Y.,Beifang Hospital of Shenyang |
Zhao J.-J.,Beifang Hospital of Shenyang |
And 2 more authors.
Tumor Biology | Year: 2014
We conducted a meta-analysis of relevant cohort studies to investigate the relationships between cyclooxygenase-2 (COX-2) protein and the prognosis of pancreatic cancer. The following electronic databases were searched without language restrictions: MEDLINE (1966∼2013), the Library Database (Issue 12, 2013), EMBASE (1980∼2013), CINAHL (1982∼2013),Web of Science (1945∼2013), and the Chinese Biomedical Database (CBM) (1982∼2013). Meta-analysis was performed using the STATA statistical software. Six cohort studies with a total of 712 pancreatic cancer patients were involved in this metaanalysis. Our findings showed that COX-2-positive patients were significantly associated with a shorter overall survival (OS) than COX-2-negative patients (hazard ratio (HR)=1.48, 95 % confidence interval (95%CI)=1.12∼1.85, P<0.001). A subgroup analysis by ethnicity also revealed that pancreatic cancer patients with an abnormal COX-2 expression exhibited a worse OS than COX-2-negative patients among both Asians and Caucasians (Asians: HR=1.40, 95%CI=−0.09∼2.89, P= 0.066; Caucasians: HR=1.49, 95%CI=1.11∼1.87, P<0.001, respectively). Our findings provide empirical evidence that abnormal COX-2 expression may be strongly correlated with poor prognosis for patients with pancreatic cancer. Thus, COX-2 protein may be a useful biomarker for pancreatic cancer. © International Society of Oncology and BioMarkers (ISOBM) 2014. Source